ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53, and mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM)
Posted on: Oct 23, 2019 09:04AM
Multigene Testing of Everyone Diagnosed With Breast Cancer Deemed Cost-Effective, and Researchers Say Policies Should Change
October 8, 2019
A study found testing all people diagnosed with breast cancer for mutations in three genes linked to a high risk of the disease — BRCA1, BRCA2, and PALB2 — would be "extremely cost-effective" compared to testing based on family history or clinical guidelines in the United States and the United Kingdom. Read more...